Hong Kong stock pharmaceutical stocks rose sharply.

Kangfang Biological-B rose more than 9%, Rongchang Biological-B rose more than 8%, and Cinda Bio rose more than 6%. Kim Siri Biotechnology, Baiji Shenzhou, Yaoming Bio, etc. followed.Hong Kong stocks technology ETF (513020) rose more than 1.2%, with a turnover of over 57 million yuan, and the net inflow of over 52 million yuan in the past 10 days.

CITIC Construction Investment Securities believes that in the past few weeks, the marginal changes in the prevention and control policies of the epidemic situation are obvious, the pharmaceutical market of Hong Kong stocks is expected to further spread, and the medium and long -term space of the core target is still clear.Entering the disclosure of the interim report, it is recommended to actively pay attention to the CXO industry that has risen in the early stage.The industry's prosperity is still high, and the mid -term performance is the most certain.

- END -